Wednesday, February 5, 2014
phytodolor
Ingredients:
Common ash (European ash) (Fraxinus excelsior L.) bark
Aspen (quaking aspen) (Populus tremula L.) bark and leaf
Goldenrod (European goldenrod) (Solidago virgaurea L.)
aerial parts
Phytodolor™ is a formula containing extracts of common ash
(Fraxinus excelsior L.) bark, aspen (Populus tremula L.) bark and
leaves, and goldenrod (Solidago virgaurea L.) aerial parts. Aspen
bark and leaves contain salicylates (Schulz, HĂ€nsel, and Tyler, 2001).
Salicylates are perhaps more widely known as constituents of willow
bark, and for the synthetic derivative acetylsalicylic acid (known as
aspirin). Salicylates are generally known for their ability to reduce inflammation,
pain, and fever. Ash preparations contain coumarins that
have anti-inflammatory and analgesic properties (Bruneton, 1999).
Goldenrod preparations contain flavonoids, saponins, and phenol
glycosides. Extracts and individual constituents have demonstrated
diuretic, anti-inflammatory, and analgesic activity (Blumenthal,
Goldberg, and Brinkmann, 2000).
Phytodolor is a combination of the extracts of common ash bark,
aspen bark and leaves, and goldenrod aerial parts in the ratio of 1:3:1.
The individual extracts are prepared according to the following plantto-
extract ratios: ash (4.5:1), aspen (4.5:1), and goldenrod (4.8:1).
The formula as a whole is standardized to contain salicin (0.75
mg/ml), salicylic alcohol (0.042 mg/ml), isofraxidin (0.015 mg/ml),
and rutin (0.06 mg/ml). The recommended dose is 20 drops (1 ml)
three to four times daily. Phytodolor is manufactured in Germany by
Steigerwald Arzneimittel GmbH and is no longer distributed in the
United States.
We reviewed three double-blind, placebo-controlled trials that examined
the use of Phytodolor to treat the pain and inflammation associated
with various degenerative rheumatic joint diseases or arthritis.
The most common degenerative disease is osteoarthritis, caused by
wear and tear on the joint. It is characterized by the breakdown of
joint cartilage and adjacent bone in the neck, lower back, knees, hips,
and/or fingers. The symptoms include pain, stiffness, and swelling in
the joints. Degeneration of the joints also occurs with rheumatoid arthritis,
an autoimmune disease in which the body’s own immune system
attacks the membranes surrounding the joints.
Common first-line treatments for relief of symptoms of degenerative
joint diseases are the nonsteroidal anti-inflammatory drugs
(NSAIDs), which include aspirin and other salicylic acid derivatives,
acetaminophen, indomethacin, ibuprofen, and diclofenac (Hardman
et al., 1996).
Prostane
Ingredients:
Salep orchid (Orchis mascula L.) tuber
Hygrophila (Astercantha longifolia Nees.) seed
Lettuce (Lactuca scariola L.) seed
Cow-itch (Mucuna pruriens (L.)DC.) seed
Elephant creeper (Argyreia speciosa [L. f.] Sweet) root
Small caltrops (Tribulus terrestris L.) fruit
Jeevanti (Leptandenia reticulataW. & A.) whole
Stone flower [Parmelia perlata (Huds.) Ach.] whole
Prostane® is manufactured by The Himalaya Drug Company in
India and distributed in the United States by Himalaya USA. Each
tablet contains 600 mg of a proprietary blend of eight herbs. Prostane
is also sold as ProstaCare®. The product is called “Speman” in the
clinical trial we reviewed. Unfortunately that trial did not include any
details on the product, so we were unable to compare the material
used in the trial to the current product.
We reviewed one study with Prostane for treatment of acute and
chronic urinary retention due to prostate enlargement. A nonmalignant
enlargement of the prostate that is common in men older than 40
years of age is called benign prostatic hyperplasia (BPH). Symptoms
of BPH include increased urinary urgency and frequency, urinary
hesitancy, intermittency, sensation of incomplete voiding, and decreased
force of the urine stream.
Benign Prostatic Hyperplasia
An open, placebo-controlled study with Prostane included 55 men
with acute and chronic urinary retention due to prostate enlargement.
Forty-seven participants had BPH, six had fibrotic disease, and two
had prostate cancer. Forty-five of the patients were treated with
Prostane and ten served as controls. Approximately 74 percent (28 of
38) of those in the treatment group with BPH had improved symptoms
and decreases in prostate size and urinary congestion after 10 to
14 days of treatment with two tablets three times daily. The other ten
in the treatment group with BPH required surgery (prostatectomy).
All men that served as controls required surgery (Mukherjee, Ghosh,
and De, 1986). The clinical efficacy of Prostane in this study was
rated as undetermined due to poor study design.
No side effects were reported in a clinical trial with 45 subjects
given two tablets three times daily for a month (Mukherjee, Ghosh,
and De, 1986).
Subscribe to:
Posts (Atom)
